T-DM1 Benefits ' Striking ' in HER2+ Early Breast Cancer T-DM1 Benefits ' Striking ' in HER2+ Early Breast Cancer

Lidia Schapira provides her perspective on a recent study of trastuzumab emtansine in residual invasive HER2+ breast cancer.Medscape Oncology

Source: Medscape Today Headlines - March 7, 2019 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news